Development to Improve VERIGRAFT´s Tissue Personalization Bioreactor GMP Process
| Reference number | |
| Coordinator | VeriGraft AB |
| Funding from Vinnova | SEK 1 000 000 |
| Project duration | November 2024 - October 2025 |
| Status | Completed |
| Venture | Utlysning Infrastruktur for the development of accurate drug treatment |
| Call | Use infrastructures to develop precision medicine |
Important results from the project
The project aimed to develop an automated process for glucose regulation in VERIGRAFT´s bioreactor process, which is used to manufacture personalized tissue-engineered vessels. The project resulted in a new bioreactor prototype and a number of improvements that will contribute to a more scalable and more compliant process for the commercial production of personalized grafts.
Expected long term effects
The results generated by the project are expected to lead to continued collaboration and development.
Approach and implementation
VERIGRAFT collaborated with CCRM Nordic as an infrastructure to to develop an automated process for glucose regulation to be used in VERIGRAFTs personalization process. CCRM Nordic was responsible for the development of prototypes and the glucose automation. VERIGRAFT coordinated the project and was responsible for testing and evaluation.